The potential for early detection through prostate-specific antigen (PSA) testing has been recognized since the 1990s, but population-based prostate cancer screening has long been controversial due to concerns about overdiagnosis and overtreatment of indolent disease [2]. The gene discussed is KLK3; the disease is prostate carcinoma.